CLN-0046: Treatment of AMD Subjects With OTX-TKI

Summary

To evaluate the safety, tolerability and efficacy of OTX-TKI for intravitreal use, in subjects who have neovascular age-related macular degeneration (AMD).

Timeline

Start

2019-02-18

Primary completion

2024-01-10

Completion

2024-01-10

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

release “In the higher-dose cohort, a decrease in intraretinal and/or subretinal fluid was seen in some subjects treated with OTX-TKI as a monotherapy.” ocutx.com ↗

release “This Phase 1 clinical trial is not powered to measure any efficacy endpoints with statistical significance.” ocutx.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OTX-TKI	Small molecule	—	Intravitreal
Background	Aflibercept	Protein / enzyme biologic	—	—
Background	Bevacizumab	Monoclonal antibody	—	—
Background	Ranibizumab	Monoclonal antibody	—	—

Indications